Pelvic inflammatory disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]

Overview

In order to decrease the risk of complications, treatment should be initiated as soon as the presumptive diagnosis has been made. Hospitalization may be necessary for patients who are pregnant, immunodeficient, and those with severe disease. Combination therapy is recommended to increase anti microbial coverage. Follow up is necessary in all treated patients and partner screening is recommended.

Medical Therapy

Treatment should be initiated as soon as the presumptive diagnosis has been made to decrease the risk of complications.^[1]
The long term prognosis is highly dependent on immediate appropriate antibiotic therapy.
Combination therapy is recommended to increase antibacterial coverage.
Patients are usually treated as outpatients.

Indications for hospital admission include:^[2]^[3]

Surgical emergencies (e.g., appendicitis) cannot be excluded
Tubo-ovarian abscess
Pregnancy
Severe illness, nausea and vomiting, or high fever
Unable to follow or tolerate an outpatient oral regimen
No clinical response to oral antimicrobial therapy.

Antibiotic therapy

Parenteral treatment

Parenteral therapy has more benefits than oral/intramuscular therapy.^[2]^[4]^[3]
Clinical experience should guide decisions regarding the transition to oral therapy, which can usually be initiated within 24–48 hours of clinical improvement.


Rout of administration	Regimen
Parenteral	Preferred: Cefotetan 2 g IV every 12 hours PLUS Doxycycline 100 mg orally or IV every 12 hours Cefoxitin 2 g IV every 6 hours PLUS Doxycycline 100 mg orally or IV every 12 hours Clindamycin 900 mg IV every 8 hours PLUS Gentamicin loading dose IV or IM (2 mg/kg), followed by a maintenance dose (1.5 mg/kg) every 8 hours. Single daily dosing (3–5 mg/kg) can be substituted Alternative: Ampicillin/Sulbactam 3 g IV every 6 hours PLUS Doxycycline 100 mg orally or IV every 12 hours

Intramuscular/Oral Treatment

Intramuscular/oral therapy can be considered for women with mild-to-moderately severe acute PID, because the clinical outcomes among women treated with these regimens are similar to those treated with intravenous therapy.^[2]
Women who do not respond to IM/oral therapy within 72 hours should be reevaluated to confirm the diagnosis and should be administered intravenous therapy.^[1]


Rout of administration	Regimen
Intramuscular/Oral	Preferred: Ceftriaxone 250 mg IM in a single dose PLUS Doxycycline 100 mg orally twice a day for 14 days with/without Metronidazole 500 mg orally twice a day for 14 days Cefoxitin 2 g IM in a single dose and Probenecid 1 g orally administered concurrently in a single dose PLUS Doxycycline 100 mg orally twice a day for 14 days with/without Metronidazole 500 mg orally twice a day for 14 days Clindamycin 900 mg IV every 8 hours PLUS Gentamicin loading dose IV or IM (2 mg/kg), followed by a maintenance dose (1.5 mg/kg) every 8 hours. Single daily dosing (3–5 mg/kg) can be substituted Alternative: Azithromycin 1 g orally once a week for 2 weeks PLUS ceftriaxone 250 mg IM single dose with Metronidazole 500 mg orally twice a day for 14 days

Follow-up

Patients should return for re-evaluation on the third day of antimicrobial therapy to evaluate the success of therapy.
Patients who do not improve within 3 days of therapy may require hospitalization, additional diagnostic tests, and/or surgical intervention.
Women with documented chlamydial or gonococcal infections have a high rate of reinfection within 6 months of treatment.
Repeat testing of all women who have been diagnosed with chlamydia or gonorrhea is recommended between 3 and 6 months after treatment, regardless of whether their sexual partners were treated.

Treatment of Sexual Partners

Male partners of women who have PID are often asymptomatic.
Both symptomatic and asymptomatic sexual partners of patients with pelvic inflammatory disease should be also be evaluated and, if necessary, treated.

References

↑ ^1.0 ^1.1 Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, Sondheimer SJ, Hendrix SL, Amortegui A, Trucco G, Songer T, Lave JR, Hillier SL, Bass DC, Kelsey SF (2002). “Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial”. Am. J. Obstet. Gynecol. 186 (5): 929–37. PMID 12015517.
↑ ^2.0 ^2.1 ^2.2 Workowski KA, Bolan GA (2015). “Sexually transmitted diseases treatment guidelines, 2015”. MMWR Recomm Rep. 64 (RR-03): 1–137. PMID 26042815.
↑ ^3.0 ^3.1 Brunham RC, Gottlieb SL, Paavonen J (2015). “Pelvic inflammatory disease”. N. Engl. J. Med. 372 (21): 2039–48. doi:10.1056/NEJMra1411426. PMID 25992748.
↑ Ford GW, Decker CF (2016). “Pelvic inflammatory disease”. Dis Mon. 62 (8): 301–5. doi:10.1016/j.disamonth.2016.03.015. PMID 27107781.

Template:WH Template:WS

[pmid12015517-1] 1.0 ^1.1 Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, Sondheimer SJ, Hendrix SL, Amortegui A, Trucco G, Songer T, Lave JR, Hillier SL, Bass DC, Kelsey SF (2002). “Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial”. Am. J. Obstet. Gynecol. 186 (5): 929–37. PMID 12015517.

[pmid26042815-2] 2.0 ^2.1 ^2.2 Workowski KA, Bolan GA (2015). “Sexually transmitted diseases treatment guidelines, 2015”. MMWR Recomm Rep. 64 (RR-03): 1–137. PMID 26042815.

[pmid25992748-3] 3.0 ^3.1 Brunham RC, Gottlieb SL, Paavonen J (2015). “Pelvic inflammatory disease”. N. Engl. J. Med. 372 (21): 2039–48. doi:10.1056/NEJMra1411426. PMID 25992748.

[pmid27107781-4] Ford GW, Decker CF (2016). “Pelvic inflammatory disease”. Dis Mon. 62 (8): 301–5. doi:10.1016/j.disamonth.2016.03.015. PMID 27107781.

[1]

[2]

[3]

[4]